Oric Pharmaceuticals Inc (ORIC) has disclosed a new risk, in the Innovation / R&D category.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Oric Pharmaceuticals Inc. faces a significant business risk due to ongoing clinical trials by other companies involving compounds similar to their own. Reports of adverse side effects or safety concerns from these trials could hinder Oric’s ability to secure regulatory approval or successfully commercialize their products. Such developments may also damage public perception and market acceptance of Oric’s product candidates. Consequently, this risk could adversely affect the company’s business, financial condition, and operational results.
The average ORIC stock price target is $18.43, implying 87.49% upside potential.
To learn more about Oric Pharmaceuticals Inc’s risk factors, click here.
Trending Articles:
- “The No. 1 Destination for the Most Talented Artists”: Netflix Stock (NASDAQ:NFLX) Notches Up as the Duffer Brothers Consider Jumping Ship
- “Breakthrough EVs”: Ford Stock (NYSE:F) Notches Up on New Battery Details
- “An Equity Stake”: Intel Stock (NASDAQ:INTC) Surges as U.S. Government May Buy In With CHIPS Act Money